ClinicalTrials.Veeva
Menu

Find clinical trials for Breast Cancer in Columbus, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Triple Negative Breast Cancer
Non-Small-Cell Lung Carcinoma
Neoplasm Metastasis
Cancer
Ovarian Cancer
Colorectal Cancer
Squamous Cell Carcinoma of Head and Neck

Breast Cancer trials near Columbus, OH, USA:

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

(ICI) on on 3-year Event Free Survival (EFS), in women with residual hormone receptor negative, HER2-negative ("triple negative") resectable breast...

Active, not recruiting
Breast Cancer
Procedure: Breast Surgery
Drug: Pembrolizumab

Phase 2

The University of Texas System (UT)
The University of Texas System (UT)

Columbus, Ohio, United States and 3 other locations

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer (Dauntless-1)

The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a ...

Active, not recruiting
Metastatic Breast Cancer
Drug: fulvestrant
Drug: PMD-026

Phase 1, Phase 2

Phoenix Molecular Designs

Columbus, Ohio, United States and 9 other locations

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)

therapy as a treatment after surgery for hormone receptor positive breast cancer.The study drugs involved in this study are:* A com...

Active, not recruiting
Breast Cancer
Hormone Receptor Positive Breast Cancer
Drug: ADJUVANT ENDOCRINE THERAPY
Combination Product: Pertuzumab+TRASTUZUMAB

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Columbus, Ohio, United States and 31 other locations

DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast...

Active, not recruiting
Breast Cancer
Drug: Adjuvant Therapy
Drug: Palbociclib

Phase 2

Criterium

Columbus, Ohio, United States and 18 other locations

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

The purpose of this study is to find out the possible anti-cancer effect of pelareorep in combination with chemotherapy \[paclitaxel\] and a ...

Active, not recruiting
Breast Cancer Metastatic
Drug: Avelumab
Drug: Paclitaxel

Phase 2

Oncolytics Biotech

Columbus, Ohio, United States and 17 other locations

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (DB-07)

DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o ...

Active, not recruiting
Metastatic Breast Cancer
Drug: Tucatinib
Drug: Durvalumab

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Columbus, Ohio, United States and 71 other locations

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)

to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast...

Active, not recruiting
Estrogen Receptor Positive Breast Cancer
HER-2 Positive Breast Cancer
Drug: palbociclib
Drug: trastuzumab

Phase 3

Alliance Foundation Trials

Columbus, Ohio, United States and 107 other locations

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main pu...

Enrolling
Hormone-receptor-positive Breast Cancer
Hormone Receptor Positive HER-2 Negative Breast Cancer
Drug: Fulvestrant
Drug: BGB-43395

Phase 1

BeOne Medicines

Columbus, Ohio, United States and 62 other locations

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)

with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two pr...

Enrolling
Hormone Receptor Positive HER-2 Negative Breast Cancer
Metastatic Breast Cancer
Drug: Alisertib
Drug: Endocrine therapy

Phase 2

Puma Biotechnology
Puma Biotechnology

Columbus, Ohio, United States and 52 other locations

CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

to test the safety of an investigational drug called CFI-402257 alone in advanced solid tumors and in combination with Fulvestrant in advanced breast...

Active, not recruiting
Breast Cancer
Advanced Solid Tumor
Drug: CFI-402257
Drug: Fulvestrant

Phase 1, Phase 2

Treadwell Therapeutics

Columbus, Ohio, United States and 3 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems